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Abstract
Background: A dysregulated stress response has been implicated in the pathogenesis
of critical illness. Sedative agents utilised in the critically unwell patient may impact
upon the stress response with a downstream negative effect on multiple organ
systems. This study was designed to assess the feasibility of investigating components
of the stress response as a sub-study of the current SPICE-III study (NCT01728558).
Methods: This pilot observational cohort study was conducted in a single intensive
care unit in Queensland, Australia. Enrolled patients were over 18 years who had been
commenced on mechanical ventilation requiring sedation for less than 12 h but
expected to remain ventilated for > 24 h. Blood samples were taken at 12 h intervals
over a 5-day period commencing at the time of enrolment, and subsequently tested
for various markers of key efferent limbs of the stress axis.
Results: The 12 patients recruited closely mirrored the population within the pilot study
used to design SPICE-III. Eighty-nine percent (107/120) of all planned blood samples were
obtained and drawn within 0 h (0–0.3) of the planned sampling time point. Time from
eligibility to enrolment was a median (IQR) 1.4 h (0.36–9.19), and time from eligibility to
the first blood sample was 4.79 h (2.0–10.61). Physiological, hormonal, metabolic and
cardiac biomarkers were consistent with an elevated stress response at baseline which
mostly normalised over the 5-day study period. Plasma noradrenaline levels correlated
with the dose of norepinephrine used.
Conclusions: A larger sub-study of the SPICE-III study is feasible. The study has
demonstrated a predictable trend of variation of the components of the blood
panel during the evolution of critical illness and supports multiple sampling time
points for the follow-up study.
Trial registration: ANZCTR.org.au, ACTRN12616001200471, Registered on 22
January 2016.
Keywords: Sedatives, Critical illness, Allostasis, Multiple organ failure
Background
Survival of an organism in the face of either internal or external events requires a measured
and appropriate stress response. It has been hypothesised that an abnormal stress response
is linked to the development and subsequent severity of multi-organ failure [1]. The
stress response is coordinated by the primitive brain structures of the diencephalon
and brainstem. It comprises a broad range of behavioural, neurohormonal, cardiovascular
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and other effects aimed at maintaining homeostasis. This biological system, developed
over millions of years, is a critical requirement for the survival of organisms ranging
from invertebrates to human beings. Conservation of this system across such a wide
variety of species points to its success in priming organisms to respond to both
internal and external change. In humans, stress is an indispensable part of learning
and development, both physiologically and psychologically. However, when there is
no escape from an inciting event, the stress response is prolonged and necessitates
physiological or behavioural change in order to compensate and maintain stability.
These changes themselves may generate sequelae or even complications for the
organism. This is exemplified by the chronic stress-related diseases of hypertension,
stroke, obesity and the metabolic syndrome [2].
Illnesses commonly treated in intensive care represent significant acute stress events.
A prolonged, severe stress can transition the acute phase of critical illness into
multi-organ failure. Organ failure is however postulated to preserve basic cellular survival
at the expense of higher functions by inducing a metabolic shutdown. This persists until
the inciting event passes and recovery is possible [3].
Critical illness may therefore represent the ultimate example of acute stress-related
decompensation. Given the key role of the central nervous system, it could be predicted
that sedating drugs, commonly utilised in the critically ill, will interfere with normal co-
ordination of the stress response and thus generate abnormal outputs. If confirmed,
this may contribute to the abnormal haemodynamics, metabolic disturbances and
organ dysfunction observed in critical illness.
A reduction in sedation level alone confers a benefit for critically ill patients by way of
reduced ventilator days, intensive care length of stay, duration of coma and mortality [4–9].
The Sedation Practices in Intensive Care Evaluation (SPICE)-III study (NCT01728558) aims
to determine whether any mortality benefit can be derived from targeting light sedation
utilising a protocolised sedation strategy. Pilot data from the SPICE-II study [10]
show that early goal-directed sedation (EGDS) results in a marked reduction in
sedation level as compared to standard practice, until approximately day 4 of
admission. The SPICE-III study offers the opportunity to study two similar groups of
patients who may have differing levels of physiological stress as a result of differing
sedation levels (EGDS strategy versus standard care). To investigate this hypothesis,
we undertook a pilot study to outline temporal changes in a panel of blood tests that
represent key efferent limbs of the stress system in response to critical illness and
sedation. The combination of tests was selected for the panel based on a combination
of factors, namely physiological relevance, minimum total required blood sample
volume and cost, in order to demonstrate feasibility and to generate baseline data to
inform protocol development for a randomised controlled study.
Methods
Design and patients
This pilot observational cohort study was conducted in a 12-bed mixed surgical/medical
general intensive care unit. The institutional human research ethics committee gave
permission for prospective consent from a patient surrogate. The study was registered
(ACTRN12616001200471) and conducted between August and December 2015.
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Inclusion and exclusion criteria were chosen such that the study population would
mirror the likely patient population in the SPICE-III study. Where relevant, data from
this pilot study were compared against the standard-care arm of the SPICE-II pilot
study [10] as this likely reflects the final population of the SPICE-III study. Sedation
practice in the standard care arm of SPICE-II most likely reflects practice in this
current study. Patients were included if they were admitted to the intensive care unit
requiring invasive mechanical ventilation and likely to remain ventilated for more than
24 h. Patients were excluded if less than 18 years of age, pregnant, had been mechanically
ventilated for more than 12 h, had been enrolled in the intervention arm of the SPICE-III
study, or admitted with a primary cardiac diagnosis, brain lesion, drug overdose, burns, a
mean arterial pressure < 50 mmHg despite adequate resuscitation, fulminant hepatic
failure, were in full-time residential nursing care prior to admission, death was felt to be
imminent or inevitable, or it was unlikely the patient would to survive to 90 days.
Study outcome measures
The main outcome measures were to determine (i) baseline variability and (ii) temporal
change in concentration of the components of a panel of blood tests (Table 1) taken
over a period of 5 days in the context of critical illness. These data would determine
the feasibility of performing blood tests on patients enrolled in the SPICE-III study in
terms of recruitment rate and adherence to a protocol of blood sampling.
Study process
Potentially eligible participants were identified by the ICU team caring for the patient.
Once informed consent was obtained either from the patient or surrogate decision
maker, patients were enrolled and blood drawn immediately from an indwelling arterial
catheter. Blood sampling was repeated every 12 h for a period of 5 days. The samples
were processed and analysed by the local hospital pathology laboratory. FT3 was
analysed using competitive binding immunoenzymatic assay, TNI by two-site immu-
noenzymatic (sandwich) quantitative assay, triglycerides, total and HDL cholesterol
were analysed by spectrophotometric timed endpoint assay (Beckman-Coulter Synchron
Clinical Systems. Brea, CA, USA). Aldosterone was analysed by liquid chromatography with
mass spectrometry (LC-MS/MS). Catecholamines were analysed by high performance
liquid chromatography (HPLC) coupled with electrochemical detection (ECD). β natriuretic
peptide (BNP) was analysed using an iSTAT point of care analyser (Abbott Point of Care
Inc. Abbott Parl, IL, USA). Ketones were analysed by FreeStyle Optimum H Blood
B-Ketone Test Strips™ (Abbott, Sydney, Australia). Baseline characteristics were recorded
for each patient including demographics and co-morbidities. Daily records were kept of
sedation level (Richmond Agitation Sedation Scale (RASS)), the severity of illness
Table 1 Panel of assays performed
Aldosterone Noradrenaline
Tri-iodothyronine (FT3) Adrenaline
Total cholesterol b-type natriuretic peptide (BNP)
High density lipoprotein (HDL) cholesterol Troponin I (TNI)
Triglycerides Ketones
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(sepsis-related organ failure assessment (SOFA) score) and medication (type and dose
of sedative, analgesic and inotropic or vasoactive agents).
Statistical analysis
Values are reported as means with standard deviation for normally distributed variables
and medians with interquartile ranges (IQRs) for non-normally distributed continuous
variables and proportions for categorical variables. Comparisons between groups have
been made using a chi-squared test for equal proportion or Fisher exact test where
numbers were small. Where appropriate, linear regression analysis was undertaken to
define the relationship between nominated predictor and outcome variables. Cross-sec-
tional time series (panel) data were analysed using a mixed effect linear model with the
patient as the panel variable. Validity of this technique was checked using a Hausman test.
Significance of the regression slope (β) and its 95% confidence interval were reported. All
models underwent residual diagnostics for distribution and homoscedasticity. For all
analyses, the level of significance was set at P < 0.05.
Results
Of the 49 patients who met all inclusion criteria, 12 were enrolled (Fig. 1). Baseline pa-
tient demographics and characteristics are shown in Table 2. Patients were admitted
from the emergency department (n = 5), general ward (n = 3), operating theatre (n = 2),
medical emergency call from the ward (n = 1) and inter-hospital transfer (n = 1). There
Fig. 1 CONSORT diagram. Of the screened patients, 2 (3.9%) did not meet inclusion criteria, 33 (64.7%) met
exclusion criteria and 4 (7.8%) were excluded based on medical decision
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were no significant differences in baseline characteristics between this population and the
standard care arm of the SPICE-II study.
Feasibility of recruitment, feasibility of blood sampling
The recruitment rate was 0.77 patients per week. No consent was revoked. Eighty-nine
percent (107/120) of all planned blood samples were obtained.
The time from eligibility to enrolment was a median (IQR) of 1.4 h (0.4–9.2), and the
time from eligibility to the first blood sample was 4.8 h (2.0–10.6). Initial blood samples
were taken within a median (IQR) of 0.7 h (0.2–2.35) of enrolment with subsequent
blood sampling done within 0.0 h (0–0.3) of the identified sampling time point
(Table 3).
Table 2 Patient characteristics and demographic data
Patient characteristics SPICE-II standard arm (n = 16) All-SPICE (n = 12) P value
Age, year; mean (SD) 61.6 (17.0) 57.09 (16.30) 0.486
Male, % (n) 9 (56%) (9) 5 (41.67%) 0.704
Weight, Kg; mean (SD) 87.0 (28.1) 91.33 (27.68) 0.688
APACHE-II; mean (SD) 18.6 (8.8) 20.08 (10.26) 0.685
Admission source
Ward referral, % (n) 25.0% (4) 33.3% (4) 0.691
Operating theatre, % (n) 25.0% (4) 16.9% (2) 0.673
Emergency department, % (n) 43.7% (7) 41.7% (5) > 0.999
Inter-hospital transfer, % (n) 6.25% (1) 8.33% (1) > 0.999
Vasopressor during study, % (n) 88% (14) 92% (11) > 0.999
APACHE II acute physiology evaluation and chronic Health Evaluation II (11)
Table 3 Feasibility and clinical outcomes
Clinical outcome SPICE-II -standard sedation
limb (n = 16)
All-SPICE OPS
(n = 12)
P value
Time from eligibility to enrolment (h), median [IQR] 1.1 [0.44–3.54] 1.4 [0.36–9.19] P = 0.71
Time from eligibility to first blood draw (h),
median [IQR]
4.79 [2.0–10.61]
Time from enrolment to first blood draw (h),
median [IQR]
0.655 [0.23–2.353]
Samples obtained, % (n) 89.2% (107/120)
Interval from planned to actual sample draw time (h),
median (IQR)
0.0 (0–0.3)
RASS − 2 to 1 first 48 h (%) 38% (74/197) 56% (33/59) 0.016*
RASS − 3 to − 5 first 48 h (%) 57% (112/197) 41% (24/59) 0.037*
Extubated within 7 days 75% (12) 75% (9) > 0.999
Ventilator free days at day 28, mean (SD) 20.1 (10.1) 20.07 (9.66) > 0.999
ICU LOS days, median [IQR] 7.0 [2.5–9.4] 6.45 [4.44] 0.471
ICU mortality, % (n) 12.5% (2) 8% (1) 0.7423
Hospital LoS, median [IQR] 17.0 [4.0–29.0] 21.15 [11.5–37.5] 0.341
Hospital mortality, % (n) 12.5 (2/16) 16.67 (2/12) > 0.999
90-day mortality, % (n) 12.5 (2/16) 16.67 (2/12) > 0.999
All results are presented as median [IQR]
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Physiological parameters
Physiological markers of stress, namely temperature, heart rate and mean arterial
pressure (MAP), are shown in Fig. 2. There was a significant drop from a median
(IQR) heart rate from 82.5 bpm (76.3–97.5) to 68.5 bpm (55.5–79) (p = 0.023) and an
increase of median (IQR) mean arterial pressure from 72.5 mmHg (64–77.5) to
95.5 mmHg (86.5–110.8). Median (IQR) core body temperature was raised at 37.7 °C
at baseline with no significant change over the study period (p = 0.16).
Blood results
Metabolic biomarkers (Fig. 3)
Total cholesterol and triglycerides showed a small but statistically significant rise over
time (both p < 0.001). HDL cholesterol levels were subnormal at baseline and displayed
no significant change over time (p = 0.99). There was a high degree of inter-individual
baseline variability in ketone levels at baseline with a significant decrease in median
level over the study period (p < 0.001). Only one patient received total parenteral
nutrition (TPN) during the study; exclusion of this patient’s results had no significant
impact on any of the above results.
Baseline median lactate levels (1.05 mmol/l [0.725–1.5]) were within the normal
range and did not vary significantly (p = 0.38) over the course of the study. Standard
base excess however increased over time (p < 0.001).
Cardiac biomarkers (Fig. 4)
In patients without a primary myocardial injury troponin I (TNI) level fell within the
normal range and showed no significant change over time (p = 0.93). Three patients
that suffered myocardial injury secondary to ischaemia, cardiac arrest and chest trauma
had correspondingly elevated troponin levels. These patients were excluded from the
analysis as they represent a discrete subgroup. Similarly, BNP levels fell mostly within
the normal range and showed no overall trend over time (p = 0.79). One patient was
excluded from the analysis due to a diagnosis of acute congestive cardiac failure.
Hormonal profile (Figs. 5 and 6)
Plasma adrenaline levels fell within the normal range throughout and showed no
significant variation over time (p = 0.93). In contrast, noradrenaline levels were over
tenfold higher than normal at baseline but fell by the end of the study period (p = 0.031).
All but one patient was prescribed norepinephrine with a median [IQR] total dose of
5.2 mg [3.6–18.8] for a median of 3.5 days [2.75–7.25]. Noradrenaline levels correlated
a b c
Fig. 2 Physiological markers of stress. Median and interquartile range for each time point. a Temperature. b
Heart rate. c Mean arterial pressure
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significantly with the administered noradrenaline dose (p < 0.001). Three patients received
vasopressin. No other vasopressor or inotrope was used.
Triiodothyronine (FT3) levels were marginally low at baseline and showed no variation
over time (p = 0.40). Aldosterone levels fell well within the normal range for supine
patients but did decrease significantly over time (p = 0.001).
Sedation depth
A mixture of sedating agents was used: 1 (8%) received dexmedetomidine, 10 (83%)
received propofol and 10 (83%) received midazolam. For analgesia, 11 (92%) received
fentanyl and 5 (42%) morphine. During the first 48 h, there was a significant difference
in the level of sedation in this study as compared to the standard care arm of the
SPICE-II study. Of all RASS scores, 33 of 59 (56%) were in the light sedation range ver-
sus 74 of 197 (38%) in the SPICE-II study (p = 0.015). On the other hand, 24 of 59
(41%) were in the deep sedation range compared to 112 of 197 (57%) in the SPICE-II
standard care group (p = 0.03) (Table 3) (Fig 7). A similar dose of propofol (9.6 mg/kg/day
a b
Fig. 3 Cardiac profile. Median and interquartile range for each time point. Normal range is represented by
the shaded area. a Troponin I, b β-Natriuretic peptide
a
d e f
b c
Fig. 4 Metabolic profile. Median and interquartile range for each time point. Normal range is represented by
the shaded area. a total cholesterol, b HDL cholesterol, c Triglycerides, d lactate, e ketones, f base excess. *
upper limit for individuals at low cardiovascular risk. $ upper limit for individuals at high cardiovascular risk
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[2.7–30.7]) was used as compared to that used in the SPICE-II study (11.3 [6.8–19.3] (p =
0.87); however, the dose of fentanyl was significantly higher (11.1 mcg/kg/day [8.1–
26.2] versus 0 mcg/kg/day [0–2.7] in the SPICE-II study. There was no significant dif-
ference in the dose of morphine used as compare to the SPICE-II study (p = 0.576)
(Table 4).
Discussion
The primary objective of this study was to demonstrate that a larger randomised
sub-study of the effects of sedation upon the various axes of the stress system is both
practical and feasible. This study utilised inclusion and exclusion criteria similar to that
required for the SPICE-III study. The enrolment of 12 patients was completed over a
15-week period. All were recruited early within the time window of the SPICE-III
study, and the delay to first blood draw was negligible. One hundred nine (90.8%) of
the required 120 blood tests were performed, with loss of samples due to lack of
indwelling vascular access device or discharge from the intensive care unit. These data
a
c d
b
Fig. 5 Hormone profile. Median and interquartile range for each time point. Normal range is represented
by the shaded area. a Adrenaline. b Noradrenaline. c FT3. d Aldosterone
Fig. 6 Correlation of administered noradrenaline dose (mcg/min) and plasma noradrenaline level (pmolL−1)
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therefore demonstrate that recruitment as a sub-study of the SPICE-III study is feasible
and adherence to study protocol is likely to be excellent.
The study population closely mirrored the population from the SPICE-II pilot study
that informed the design of the larger SPICE-III study. Sedation practice at the time in
the participating unit utilised midazolam and propofol in preference to dexmedetomidine
with a standard prescription of a RASS target range and no protocolised weaning
regimen. This practice most resembled the standard care arm of the SPICE-II study.
Consequently, all comparisons are made to these patients only. There was a significantly
lighter level of sedation reached in our study with a correspondingly lower propofol dose.
This difference likely reflects unit practice. For the follow-up study, the utilisation of
multiple other sites may negate this difference.
We chose a number of variables thought likely to represent key efferent limbs of the
stress axes to study changes over time in critically unwell patients following the commence-
ment of sedation to facilitate mechanical ventilation. Each behaved differently during the
observation period. Several changed significantly, reflecting a predicted pattern of stress
response secondary to critical illness and its progressive resolution over time. Physiological
parameters demonstrate a modest level of stress at baseline with an improvement over the
Fig. 7 Richmond Agitation Sedation Scale (RASS) scores in the first 48 h. In the first 48 h, a total of 59 RASS
scores were performed. Most of the scores were in the light sedation range (55%)
Table 4 Cumulative dose/kg body weight and duration of treatment with sedatives and analgesic
agents throughout the study period
Drugs given Standard care n = 16 No. treated All-SPICE n = 12 No. treated P value
Dexmedetomidine (mcg/kg/day) 0 [0–0] 1 0 [0–0] 1 0.7460
Time on dexmedetomidine (day) 0 [0–0] 0 [0–0] > 0.9999
Propofol (mg/kg/day) 11.33 [6.77–19.29] 16 9.63 [2.74–30.7] 11 0.8667
Time on propofol (day) 2.5 [2.0–4.5] 1.0 [0.5–3.0] 0.0139*
Midazolam (mg/kg/day) 0.037 [0–0.18] 8 0.010 [0–1.17] 10 0.466
Time on midazolam (day) 0.5 [0.0–2.0] 2.0 [1.0–4.0] 0.0283*
Fentanyl (mcg/kg/day) 0 [0–2.67] 7 11.14 [8.08–26.18] 11 0.0002*
Morphine (mg/kg/day) 0.153 [0–0.59] 10 0.20 [0–1.99] 6 0.576
Values are expressed as median [interquartile range]
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time course of the study. Ketones, aldosterone, and lactate were elevated at baseline and fell
to normal levels. There was also a significant drop in noradrenaline level over time;
however, this is at least partially explained by reductions in the dose of administered
norepinephrine. Triglyceride levels were at the upper limit of normal at study com-
mencement and increased further during the study period. This reflects the normal
response to critical illness and is a manifestation of increased lipolysis. Propofol was
used in low doses only and for a short period so is unlikely to have contributed
significantly to triglyceride levels. On the other hand, HDL cholesterol levels were
low, a finding reflected by many other studies of critical illness [11, 12] and remained
low during the time course of the study.
Conclusion
This study has demonstrated that conduct of a larger sub-study of the SPICE-III study
assessing the stress response of critical illness and modification by sedation regimen is
feasible. The study has demonstrated a predictable trend of variation of the components of
the blood panel during the evolution of critical illness during an intensive care admission
following commencement of mechanical ventilation. In order to determine the effects of
sedation level upon the components of the blood test panel, it is advisable to undertake
sequential blood tests over several days.
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